Immeuble Le Sunway
259-261 Avenue Jean JaurEs
33 4 37 37 20 10
Full-time employees: 55
|Mr. Thomas Kuhn M.B.A., Pharm.D., Pharm D MBA||Co-Founder, CEO & Director||398.54k||N/A||N/A|
|Dr. Sébastien Bolze Ph.D., Pharm.D., Pharm D Ph.D.||Co-Founder, COO & Exec. VP||N/A||N/A||N/A|
|Dr. Pascale Fouqueray-Grellier M.D., Ph.D.||Co-Founder and Exec. VP of Clinical Devel. & Regulatory Affairs||N/A||N/A||N/A|
|Dr. Sophie Hallakou-Bozec Ph.D.||Co-Founder and Sr. VP of R&D Pharmacology & Scientific Communication||N/A||N/A||N/A|
|Ms. Anne Renevot||Exec. VP & CFO||N/A||N/A||N/A|
|Dr. David E. Moller M.D.||Exec. VP & Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Elizabeth Woo M.B.A.||Sr. VP of Investor Relations, Corp. Communications & PR||N/A||N/A||N/A|
|Mr. Quentin Durand||Exec. VP, Chief Legal Officer & Head of CSR||N/A||N/A||N/A|
|Sylvie Bertrand||VP of HR||N/A||N/A||N/A|
|Mr. Noah D. Beerman MBA||Exec. VP of Bus. Devel. & Pres of US Operations||N/A||N/A||1962|
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). Poxel S.A. has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. The company was incorporated in 2009 and is headquartered in Lyon, France.
Poxel S.A.’s ISS governance QualityScore as of 1 March 2023 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 4; Compensation: 10.